← Back

Novartis AG

Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. It was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories and operates globally across multiple therapeutic areas.:contentReference[oaicite:0]{index=0}

Official WebsiteWikipedia

Text source: Wikipedia

Andreas Clemens × Novartis AG — Employment Period

Overall Period

2014 − present

Titles Held

06/2024 − present

Global Head / Executive Director Medical Affairs Immunology, Secukinumab

2023 − 2024

Global Head Medical Affairs Strategy Autoinflammatory Disease & Ocular Gene Therapy

2021 − 2023

VP, Head New Brand Medical Incubator & Rare Disease Unit, Europe

2017 − 2021

Executive Medical Director Europe, Ophthalmology

2015 − 2017

Medical Franchise Head Europe, Respiratory / Cardiometabolic

2014 − 2015

Medical Franchise Head Europe, Primary Care

Achievements

  • Global leadership and strategic direction for Secukinumab as Executive Medical Director Immunology, overseeing global medical affairs strategy and execution in immunology.
  • Global leadership of Medical Affairs strategy for autoinflammatory diseases and inherited retinal dystrophies, delivering comprehensive go-to-market and development plans.
  • Establishment and leadership of the New Brand Medical Incubator Europe as well as successful integration of Alcon Pharma.
  • Management of teams with more than 40 colleagues using a "one team" approach within a mixed matrix structure to achieve ambitious vision in One Medical.
  • Collaborative development of early Integrated Evidence Plans (IEP) tailored to country needs for new upcoming brands, working closely with the Development Organization and Explorer Team.
  • Strategic transformation of healthcare systems in the Rare Disease Unit to impact lives of millions of patients in Europe.
  • Global leadership and strategic direction of Medical Affairs in the areas of immunology, ophthalmology, autoinflammatory diseases and ocular gene therapy.
  • Development and implementation of go-to-market, strategy and development plans for several international products.
  • Responsibility for international product launches, including
    • ULTIBRO
    • BROLUCIZUMAB (first single-chain antibody fragment against VEGF for intraocular application)
    • COSENTYX (new dermatology indication).
  • Executive leadership across multiple franchises with increasing responsibility for Primary Care (Cardiology/Metabolism), Respiratory, and Ophthalmology franchises, providing broad management experience across different therapeutic areas and commercial settings.
  • Medical leadership of the Ophthalmology Franchise including both prescription and OTC portfolio covering Retina, Glaucoma and external eye diseases (EED).
  • Active membership in Franchise Leadership Teams contributing to Global Portfolio Strategy, inlicensing decisions, and development decisions.
  • Assessment, release and oversight of all Phase IV clinical trial activities in Region Europe across respective franchises, managing more than 100 clinical trials.
  • Management of 2 Medical Directors and via matrix structure a group of approximately 12 local Medical Heads in Europe.
  • Matrix management of countries and clusters with more than 50 countries, supporting affiliates through regional meetings and scientific events including stand-alone meetings and preceptorships.
  • Active driving of strategy implementation, excellence in execution (Medicine; local TAHs and MSLs) and Market Access in Europe.
  • Ensuring scientific integrity, worldwide GCP compliance and responsibility for safety design of clinical trials.
  • Managing a business volume of approximately 6 billion USD.
  • Building sustainable partnerships with the international scientific community.
  • >130 peer-reviewed publications, active scientific collaboration with external experts as well as extensive contributions to congresses, advisory boards and think tanks.
Novartis AG - Employment Period of Dr. Andreas Clemens | Dr. Andreas Clemens